Abstract: An abuse-deterrent formulation comprising an abuse-prone drug encapsulated in nanoparticles, a gel-forming polymer, and pharmaceutically acceptable excipients; method of use; and method of making.

Abstract: Methods for applying a therapeutic agent coating to an extended-wear device and the systems created thereby are disclosed. For example, a method for coating an extended-wear device using N-TIPS provides therapeutic agent coating for localized treatment in a patient using an extended-wear device for monitoring or treatment of illness or injury, wherein such methods can be used on polymeric films or within polymeric tubes.

Abstract: Nanoconstructs and compositions comprising a nanoparticle coated with an immunoadjuvant (e.g. ATP) and comprising one or more therapeutic agents (e.g. ICD inducer) encapsulated therein; and methods for treating cancer in a subject using such nanoconstructs and compositions, as well as combination immunotherapies.

Abstract: The present disclosure generally relates to a composition matter and a method for cancer treatment. In particular, a composition matter as an antitumor immunotherapy comprising a polyethyleneimine derivative as an immunoadjuvant, a chemotherapeutic drug, and optional components such as a microRNA, messenger RNA, plasmid DNA, siRNA, oligonucleotide, or a cyclic dinucleotide. A method for treating a subject with a cancer by administrating a therapeutic effective amount of a composition comprising a polyethyleneimine derivative and an antitumor agent to the subject in need of relief from said cancer is also within the scope of this disclosure.

Abstract: The present invention generally relates to a process of nanoparticle formulations and its composition matter for systemic treatment of sepsis. In particular, this invention discloses a method for preparing tannic acid-ferric nanoparticles, optionally incorporating a component of vitamin D3, coated with zwitterionic chitosan (ZWC) and polymyxin B (PMB). The invention described herein also pertains to pharmaceutical compositions and methods for the treatment of sepsis.

Abstract: The present invention generally relates to a process of nanoparticle formulations and its composition matter for systemic treatment of sepsis. In particular, this invention discloses a method for preparing tannic acid-ferric nanoparticles, optionally incorporating a component of vitamin D3, coated with zwitterionic chitosan (ZWC) and polymyxin B (PMB). The invention described herein also pertains to pharmaceutical compositions and methods for the treatment of sepsis.

Abstract: A formulation to deter abuse of a drug by smoking comprising a physical barrier having properties to entrap the drug and thermal degradation products thereof. The physical barrier is in the form of an additive or a polymer network or a combination thereof.

Abstract: The present disclosure generally relates to a composition matter and a method for cancer treatment. In particular, a composition of soft, non-cationic nanocapsules, termed Nanosac, for systemic delivery of siRNA. Nanosac is produced by sequential attachment of siRNA and polydopamine on a sacrificial MSN core, followed by removal of the MSN. Encapsulating siRNA in the capsules, Nanosac avoids the issues common to cationic gene carriers, such as toxicity and non-specific protein binding while protecting siRNA from RNase. Nanosac entered tumor cells by caveolae-mediated endocytosis, likely via albumin recruited from serum, trafficked to the cytosol, and silenced target genes.

Abstract: Drug delivery devices that have a flexible film, an array of nanoscopic, porous needles attached to a surface of the flexible film, and a therapeutic drug cargo loaded onto the needles. The drug delivery device may be applied to living tissue such that the surface of the flexible film contacts the living tissue and some or all of the needles are inserted into the tissue. The flexible film may then be dissolved while leaving the needles inserted in the tissue. The needles degrade in the living tissue over time causing release of the therapeutic drug cargo loaded onto the needles.

Abstract: The present invention relates to pharmaceutical formulations for long-term ocular delivery of the active agents. The present invention further provides the long-term ocular delivery of griseofulvin with specific in vitro release profile. These formulations are used for the treatment of neovascular eye diseases and age-related macular degeneration (AMD). In particular, the present invention provides microparticles & nanoparticles of griseofulvin for the long-term ocular delivery and methods of preparation of such formulations.

Abstract: The present disclosure generally relates to a composition matter and a method for cancer treatment comprising albumin (alb) coated tannic acid-Fe nanoparticles (NPs) with a therapeutic compound, and one or more diluents, excipients or carriers. In particular, the present invention provides a treatment by enhancing antitumor immunity using tannic acid-based nanoparticles containing a therapeutic cancer treatment that can induce immunogenic cell death (ICD). The method disclosed herein provides a potential solution to the immunotoxicity accompanying the ICD cancer immunotherapy by intratumoral or intravenous administration of a nanocapsule formulation of carfilzomib (CFZ), an ICD-inducing proteasome inhibitor, using interfacial supramolecular assembly of tannic acid (TA) and iron, supplemented with albumin coating for better metabolic stability.

Abstract: The present invention generally relates to a process of nanoparticle formulations and its composition matter for systemic treatment of sepsis. In particular, this invention discloses a method for preparing tannic acid-ferric nanoparticles, optionally incorporating a component of vitamin D3, coated with zwitterionic chitosan (ZWC) and polymyxin B (PMB). The invention described herein also pertains to pharmaceutical compositions and methods for the treatment of sepsis.

Abstract: The present invention generally relates to a method for preparing a drug-loaded liposome, in particular to a method for preparing a drug-loaded liposome manufactured using hypertonic loading or a combination of hypertonic loading and remote loading of one or more drugs. The invention described herein also pertains to pharmaceutical compositions and methods for treating cancers. Both the manufacturing processes and the pharmaceutical products are within the scope of this disclosure.

Abstract: Drug delivery devices that have a flexible film, an array of nanoscopic, porous needles attached to a surface of the flexible film, and a therapeutic drug cargo loaded onto the needles. The drug delivery device may be applied to living tissue such that the surface of the flexible film contacts the living tissue and some or all of the needles are inserted into the tissue. The flexible film may then be dissolved while leaving the needles inserted in the tissue. The needles degrade in the living tissue over time causing release of the therapeutic drug cargo loaded onto the needles.

Abstract: The present invention generally relates to targeted nanoparticle delivery to E-selectin- or P-selectin-positive cells or tissues. In particular, this invention discloses a method for preparing quinic acid-modified nanoparticles for targeted drug delivery to cancerous cells or tissues via E-selectin- or P-selectin-mediated transcytosis. The invention described herein also pertains to pharmaceutical compositions and methods for treating cancers.

Abstract: The invention provides siRNA compositions that specifically downregulates expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD).

Abstract: The invention provides siRNA compositions that specifically downregulates expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD).

Abstract: The present invention generally relates to targeted nanoparticle delivery to E-selectin- or P-selectin-positive cells or tissues. In particular, this invention discloses a method for preparing quinic acid-modified nanoparticles for targeted drug delivery to cancerous cells or tissues via E-selectin- or P-selectin-mediated transcytosis. The invention described herein also pertains to pharmaceutical compositions and methods for treating cancers.

Abstract: The invention provides siRNA compositions that specifically downregulates expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD).

Abstract: A carrier free nanoparticle formulation with good circulation stability is made for anticancer drug delivery. Nanocrystals crystallized in the medium containing Pluronic F-127 then coated with albumin (Cim-F-Alb) had the smallest size and the most native albumin, and showed most favorable cell interaction profiles and better stability than commercial albumin based Abraxane formulation, while maintaining comparable cytotoxicity to those of Abraxane and solvent-dissolved paclitaxel (PTX).